An HMGCR inhibitor, simvastatin (Table 1), delays PanIN progression in KC mice (Pdx1-Cre; lox-stop-lox-KrasG12D/+) and attenuates pancreatic cancer development in KPC (Pdx1-Cre; lox-stop-lox-KrasG12D/+; lox-stop-lox-Trp53R172H/+) mice [25]. Here, HMGCR is linked to pancreatic neoplasm.